A Phase 2/3 interventional study of Pericapsular nerve group block using bupivicaine and magnesium sulphate in Hip Fractures, sponsored by Assiut University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-12-22.
Sponsored by Assiut University · Phase 2/3, Interventional, and Treatment
Our aim will be to compare the analgesic efficacy and safety of magnesium sulphate as an adjuvant to bupivacaine in pericapsular nerve group block in Hip joint surgeries.
822 studies on the registry are indexed under Hip Fractures; 160 are open to participants now.
This study's planned enrollment of 62 is below the median of 90 across 529 interventional studies indexed under Hip Fractures.
Browse Hip Fractures studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients aged 18 years or more.
Exclusion Criteria:
Patient refusal of peripheral nerve block
will have Peng block using 20mg bupivacaine 0.25%
will have PENG block with 2mg magnesium sulphate 10% as an adjuvant to 20mg of bupivacaine 0.25%
Drug: Pericapsular nerve group block using bupivicaine and magnesium sulphate
This technique involves the deposition of the local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus
Postoperative pain management
total amount of postoperative morphine consumption in the first 24 hours postoperatively.
Time frame: 24 hours postoperatively
Visual analog scale
It's a scale from 0 to 10 where 0 means no pain and 10 means worst pain imaginable
Time frame: 24 hours postoperatively
This study is not yet recruiting, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University